DIA
Drug Information Association Logo

Burden of Post-treatment Fractures in Terms of Health Care Cost and Utilization Among Patients on Osteoporosis Treatment

Time

Wed, Jun 26 11:45AM
W 28

Title

Burden of Post-treatment Fractures in Terms of Health Care Cost and Utilization Among Patients on Osteoporosis Treatment

Abstract Summary

A retrospective matched case-control study using i3 Invision Datamart from 2001-2011 (study period) was conducted. Women 55 years or older who had at least 1 OP medication prescription during study period and continuous enrollment of at least 1 year before and at least 2 years after treatment initiation were included. Patients with Paget's disease and malignant neoplasms in the study period were excluded. OP medication included alendronate, risedronate, ibandronate, zolendronate, raloxifene, calcitonin and teriparatide. Among patients who met selection criteria, those who had an OP-related fracture within 12 months after treatment initiation were classified into the fracture (case) cohort, and those who had no OP-related fractures within 24 months after treatment initiation were classified into the non-fracture (control) cohort. Index date for cases was defined as the date of first post-treatment OP-related fracture and index date for controls was a random assignment of date based on empirical distribution of index date in entire case cohort. Cases were matched to controls on using propensity scores controlling for patient characteristic such as age, gender, pre-treatment fractures, prior use of gastro-protective agents, NSAIDS, estrogen, and Charlson comorbidity index. Health care resource utilization and health care costs during the 12 months post-index (follow-up) were examined in both groups using McNemar’s test and signed rank test, respectively.

Poster Presenter

Arun Krishna
PhD,
Outcome Research Scientist,
Merck & Co., Inc.
United States

© 2015 DIA